Viewing Study NCT02847156


Ignite Creation Date: 2025-12-24 @ 11:28 PM
Ignite Modification Date: 2026-01-03 @ 6:29 PM
Study NCT ID: NCT02847156
Status: COMPLETED
Last Update Posted: 2016-07-28
First Post: 2016-07-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis.
Sponsor: Hospices Civils de Lyon
Organization:

Study Overview

Official Title: Clinical and Microbiological Impact of Respiratory Viral Infections in the Short and Medium Term in Infants (<24 Months) With Cystic Fibrosis.
Status: COMPLETED
Status Verified Date: 2016-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PREVIMUC
Brief Summary: Respiratory Viral Infections (RVI) are particularly frequent in young children. Old data mention the deleterious role of some viruses such as the Respiratory Syncytial Virus in young children with cystic fibrosis (CF). However, recent epidemiological data on RVI in CF children are rare and the impact of most frequent viruses such as human rhinoviruses is usually not correctly evaluated.

The aim of this study is to assess the frequency of lower and upper RVI during a 1 year follow-up in CF infants and to evaluate the impact of RVI at a clinical, microbiological and therapeutic level.

Our hypothesis is that frequent and/or clinically severe RVIs have the worst impact in the short term and without any particular link with a specific virus as previously described.
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: